This protocol addresses the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in adults presenting with compensated MASH-related cirrhosis — a stage that requires a distinct, specifically defined clinical approach.
The patient carries metabolic dysfunction-associated steatohepatitis (MASH)-related cirrhosis at the compensated stage. This diagnosis shapes which interventions are applicable and which are explicitly not recommended at this point in the disease course.
No MASH-targeted pharmacotherapy can currently be recommended for adults with MASH at the cirrhotic stage. Management priorities consequently shift toward a different set of clinical actions tailored to this stage.
Management in this setting may include liver transplantation as a relevant clinical consideration. The structured protocol defines the complete pathway, including all applicable components and the criteria governing each step.